Tối đa hóa thời gian kiểm soát bệnh trong ung thư thận di căn bằng các tác nhân nhắm mục tiêu: thỏa thuận của các chuyên gia

citation_journal_title=J Clin Oncol; citation_title=Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial; citation_author=B Escudier; citation_volume=27; citation_publication_date=2009; citation_pages=3312-3318; citation_doi=10.1200/JCO.2008.19.5511; citation_id=CR1 citation_journal_title=J Clin Oncol; citation_title=Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival; citation_author=B Escudier; citation_volume=28; citation_publication_date=2010; citation_pages=2144-2150; citation_doi=10.1200/JCO.2009.26.7849; citation_id=CR2 citation_journal_title=N Engl J Med; citation_title=Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma; citation_author=G Hudes; citation_volume=356; citation_publication_date=2007; citation_pages=2271-2281; citation_doi=10.1056/NEJMoa066838; citation_id=CR3 citation_journal_title=J Clin Oncol; citation_title=Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma; citation_author=RJ Motzer; citation_volume=27; citation_publication_date=2009; citation_pages=3584-3590; citation_doi=10.1200/JCO.2008.20.1293; citation_id=CR4 citation_journal_title=Cancer; citation_title=Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors; citation_author=RJ Motzer; citation_volume=116; citation_publication_date=2010; citation_pages=4256-4265; citation_doi=10.1002/cncr.25219; citation_id=CR5 citation_journal_title=J Clin Oncol; citation_title=Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206; citation_author=BI Rini; citation_volume=28; citation_publication_date=2010; citation_pages=2137-2143; citation_doi=10.1200/JCO.2009.26.5561; citation_id=CR6 citation_journal_title=J Clin Oncol; citation_title=A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC); citation_author=CN Sternberg; citation_volume=28; citation_publication_date=2010; citation_pages=1061-1068; citation_doi=10.1200/JCO.2009.23.9764; citation_id=CR7 citation_journal_title=Med Oncol; citation_title=Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma; citation_author=H Gerullis; citation_volume=27; citation_publication_date=2010; citation_pages=373-378; citation_doi=10.1007/s12032-009-9220-1; citation_id=CR8 citation_journal_title=Ann Oncol; citation_title=Temsirolimus in VEGF-refractory metastatic renal cell carcinoma; citation_author=MJ Mackenzie; citation_volume=22; citation_publication_date=2011; citation_pages=145-148; citation_doi=10.1093/annonc/mdq320; citation_id=CR9 citation_journal_title=Expert Rev Anticancer Ther; citation_title=Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer; citation_author=AS Merseburger, A Simon, S Waalkes, MA Kuczyk; citation_volume=9; citation_publication_date=2009; citation_pages=1429-1434; citation_doi=10.1586/era.09.96; citation_id=CR10 Porta C, Paglino C, Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. Eur J Clin Med Oncol. 2010;4. citation_journal_title=J Clin Oncol; citation_title=Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma; citation_author=BI Rini; citation_volume=27; citation_publication_date=2009; citation_pages=4462-4468; citation_doi=10.1200/JCO.2008.21.7034; citation_id=CR12 Porta C, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011. (E-pub ahead of print). NCT00678392: Axitinib (AG 013736) as second line therapy for metastatic renal cell cancer. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT00678392 . Accessed 2011. NCT00502307: A study of tivozanib (AV-951), an oral VEGF receptor tyrosine kinase inhibitor, in the treatment of renal cell carcinoma. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT00502307 . Accessed 2011. NCT01223027: Study of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT01223027 . Accessed 2011. citation_journal_title=Cancer Treat Rev; citation_title=Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma; citation_author=C Porta, J Bellmunt, T Eisen, C Szczylik, P Mulders; citation_volume=36; citation_publication_date=2010; citation_pages=16-23; citation_doi=10.1016/j.ctrv.2009.09.001; citation_id=CR17 citation_journal_title=Lancet Oncol; citation_title=Resistance to targeted therapy in renal-cell carcinoma; citation_author=BI Rini, MB Atkins; citation_volume=10; citation_publication_date=2009; citation_pages=992-1000; citation_doi=10.1016/S1470-2045(09)70240-2; citation_id=CR18 citation_journal_title=Br J Cancer; citation_title=Sunitinib and other targeted therapies for renal cell carcinoma; citation_author=T Powles; citation_volume=104; citation_publication_date=2011; citation_pages=741-745; citation_doi=10.1038/sj.bjc.6606061; citation_id=CR19 citation_journal_title=Oncologist; citation_title=Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review; citation_author=SS Agarwala, S Case; citation_volume=15; citation_publication_date=2010; citation_pages=236-245; citation_doi=10.1634/theoncologist.2009-0141; citation_id=CR20 citation_journal_title=Mol Cancer Ther; citation_title=Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study; citation_author=HJ Hammers; citation_volume=9; citation_publication_date=2010; citation_pages=1525-1535; citation_doi=10.1158/1535-7163.MCT-09-1106; citation_id=CR21 Mier JW. Acquired resistance to VEGF receptor blockade: underlying mechanism and therapeutic options. ASCO 2009 Genitourinary Cancers Symposium, 26–28 February 2009, Orlando, USA; 2009. Available at http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=64&trackID=40&sessionID=2855 . citation_journal_title=J Clin Oncol; citation_title=Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer; citation_author=G Di Lorenzo; citation_volume=27; citation_publication_date=2009; citation_pages=4469-4474; citation_doi=10.1200/JCO.2009.22.6480; citation_id=CR23 citation_journal_title=Cancer; citation_title=Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab; citation_author=JA Garcia; citation_volume=116; citation_publication_date=2010; citation_pages=5383-5390; citation_doi=10.1002/cncr.25327; citation_id=CR24 Mancuso AP, et al. Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment. J Clin Oncol. 2009;27:abstr e16027. Sepulveda J, et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): Analysis for safety and activity on sunitinib progressive pts. J Clin Oncol. 2008;26(15):abstract 16100. Buchler T, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. Ann Oncol. 2011;(E-pub ahead of print). citation_journal_title=Ann Oncol; citation_title=Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (mRCC); citation_author=TK Choueiri; citation_volume=19; citation_publication_date=2008; citation_pages=viii191; citation_id=CR28 citation_journal_title=Cancer; citation_title=Sequential therapy with sorafenib and sunitinib in renal cell carcinoma; citation_author=AZ Dudek, J Zolnierek, A Dham, BR Lindgren, C Szczylik; citation_volume=115; citation_publication_date=2009; citation_pages=61-67; citation_doi=10.1002/cncr.24009; citation_id=CR29 citation_journal_title=Eur Urol; citation_title=Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis; citation_author=C Eichelberg; citation_volume=54; citation_publication_date=2008; citation_pages=1373-1378; citation_doi=10.1016/j.eururo.2008.07.051; citation_id=CR30 citation_journal_title=Onkologie; citation_title=Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib; citation_author=S Richter, D Pfister, D Thur, UH Engelmann, A Heindenreich; citation_volume=31; citation_issue=4; citation_publication_date=2008; citation_pages=234; citation_id=CR31 citation_journal_title=J Urol; citation_title=Sequential sorafenib and sunitinib for renal cell carcinoma; citation_author=MP Sablin; citation_volume=182; citation_publication_date=2009; citation_pages=29-34; citation_doi=10.1016/j.juro.2009.02.119; citation_id=CR32 citation_journal_title=J Urol; citation_title=Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy; citation_author=I Tamaskar; citation_volume=179; citation_publication_date=2008; citation_pages=81-86; citation_doi=10.1016/j.juro.2007.08.127; citation_id=CR33 citation_journal_title=Oncology; citation_title=Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib; citation_author=K Zimmermann; citation_volume=76; citation_publication_date=2009; citation_pages=350-354; citation_doi=10.1159/000209961; citation_id=CR34 citation_journal_title=Eur Urol; citation_title=Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib; citation_author=R Heuer, C Eichelberg, M Zacharias, H Heinzer; citation_volume=8; citation_publication_date=2009; citation_pages=183; citation_id=CR35 citation_journal_title=Eur J Cancer Suppl; citation_title=Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics; citation_author=S-T Wang; citation_volume=7; citation_publication_date=2009; citation_pages=436; citation_id=CR36 citation_journal_title=Cancer Cell; citation_title=Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis; citation_author=M Paez-Ribes; citation_volume=15; citation_publication_date=2009; citation_pages=220-231; citation_doi=10.1016/j.ccr.2009.01.027; citation_id=CR37 NCT00732914: Sequential study to treat renal cell carcinoma. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT00732914 . Accessed 2011. Tannir NM, et al. Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. J Clin Oncol. 2010;28(15):abstract 4527. citation_journal_title=Ann Oncol; citation_title=A phase II trial of pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab; citation_author=JD Hainsworth; citation_volume=21; citation_issue=8; citation_publication_date=2010; citation_pages=vii285; citation_id=CR40 NCT00920816: Axitinib (AG-013736) for the treatment of metastatic renal cell cancer. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT00920816 . Accessed 2011. NCT01076010: An extension treatment protocol for subjects who have participated in a Phase 3 study of tivozanib versus sorafenib in renal cell carcinoma (protocol AV-951-09-301). ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT01076010 . Accessed 2011. citation_journal_title=Lancet; citation_title=Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial; citation_author=RJ Motzer; citation_volume=372; citation_publication_date=2008; citation_pages=449-456; citation_doi=10.1016/S0140-6736(08)61039-9; citation_id=CR43 citation_journal_title=Eur J Cancer Suppl; citation_title=Randomized, placebo-controlled, phase 3 study of everolimus, a novel therapy for patients with metastatic renal cell carcinoma: subgroup analysis of patients progressing on prior bevacizumab therapy; citation_author=T Hutson, S Negrier, A Kay; citation_volume=7; citation_publication_date=2009; citation_pages=434; citation_id=CR44 Schwandt A, et al. Temsirolimus in metastatic RCC: safety and efficacy in patients previously treated with VEGF-targeted therapy. J Clin Oncol. 2009;27(15):abstract 5116. Wood L, Bukowski RM, Dreicer R et al. Temsirolimus in metastatic RCC: safety and efficacy in patients previously treated with VEGF-targeted therapy. ASCO Genitourinary Cancers Symposium 2008. Available at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20313 . citation_journal_title=Urology; citation_title=Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy; citation_author=MM Vickers; citation_volume=76; citation_publication_date=2010; citation_pages=430-434; citation_doi=10.1016/j.urology.2009.12.031; citation_id=CR47 Heng DY, et al. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy. J Clin Oncol. 2011;29(7):abstract 305. Nozawa M, Matsumura N, Yasuda M, Okuda Y, Uemura H. Activity of retreatment with sorafenib for metastatic renal cell carcinoma. J Clin Oncol. 2011;29(7):abstract 404. citation_journal_title=Cancer; citation_title=Sunitinib rechallenge in metastatic renal cell carcinoma patients; citation_author=IN Zama; citation_volume=116; citation_publication_date=2010; citation_pages=5400-5406; citation_doi=10.1002/cncr.25583; citation_id=CR50 citation_journal_title=Nature; citation_title=Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes; citation_author=GL Dalgliesh; citation_volume=463; citation_publication_date=2010; citation_pages=360-363; citation_doi=10.1038/nature08672; citation_id=CR51 citation_journal_title=World J Urol; citation_title=Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma; citation_author=E Herrmann; citation_volume=29; citation_publication_date=2011; citation_pages=361-366; citation_doi=10.1007/s00345-011-0673-4; citation_id=CR52 citation_journal_title=Biochem Biophys Res Commun; citation_title=Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor; citation_author=R Roskoski; citation_volume=356; citation_publication_date=2007; citation_pages=323-328; citation_doi=10.1016/j.bbrc.2007.02.156; citation_id=CR53 citation_journal_title=J Biol Chem; citation_title=Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting; citation_author=I Plaza-Menacho; citation_volume=282; citation_publication_date=2007; citation_pages=29230-29240; citation_doi=10.1074/jbc.M703461200; citation_id=CR54 citation_journal_title=Cancer Res; citation_title=BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis; citation_author=SM Wilhelm; citation_volume=64; citation_publication_date=2004; citation_pages=7099-7109; citation_doi=10.1158/0008-5472.CAN-04-1443; citation_id=CR55 citation_journal_title=Br J Cancer; citation_title=Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors; citation_author=R Kumar; citation_volume=101; citation_publication_date=2009; citation_pages=1717-1723; citation_doi=10.1038/sj.bjc.6605366; citation_id=CR56 citation_journal_title=Expert Opin Investig Drugs; citation_title=Axitinib for renal cell carcinoma; citation_author=G Sonpavde, TE Hutson, BI Rini; citation_volume=17; citation_publication_date=2008; citation_pages=741-748; citation_doi=10.1517/13543784.17.5.741; citation_id=CR57 citation_journal_title=Cancer Treat Rev; citation_title=Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma; citation_author=M Schmidinger, J Bellmunt; citation_volume=36; citation_publication_date=2010; citation_pages=416-424; citation_doi=10.1016/j.ctrv.2010.01.003; citation_id=CR58 Elfiky AA, et al. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. 2010;(E-pub ahead of print). Kontovinis L, et al. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol. 2011;(E-pub ahead of print). NCT00903175: Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3). ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT00903175 . Accessed 2011. NCT00474786: Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT00474786 . Accessed 2011. NCT01064310: Patient preference study of pazopanib versus sunitinib in advanced or metastatic kidney cancer (PISCES). ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT01064310 . Accessed 2011. NCT01217931: Sequential two-agent assessment in renal cell carcinoma therapy. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT01217931 . Accessed 2011.